Simeone named upcoming chair of Pancreatic Cancer Action Network scientific board
Diane Simeone, M.D., director of the Pancreatic Cancer Center at the University of Michigan, was recently named the upcoming chair of the National Scientific and Medical Advisory Board for the Pancreatic Cancer Action Network. Her two-year term as chair runs from 2017 to 2019. Simeone will serve as chair-elect until then.
The Pancreatic Cancer Action Network is a national organization dedicated to creating hope for patients with pancreatic cancer through research, patient support, community outreach and government advocacy. The organization funds research directly and advocates for more aggressive federal research funding in prevention, early diagnosis and treatment of pancreatic cancer.
“I’d like to congratulate Dr. Simeone on her role as chair-elect for our Scientific and Medical Advisory Board,” says Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “Dr. Simeone has been a longtime adviser to the organization and is very dedicated to making progress against this disease. We look forward to working with her in this new capacity as we work toward our goal to double pancreatic cancer survival by 2020.”
The Pancreatic Cancer Action Network’s Scientific and Medical Advisory Board is composed of leading cancer scientists and clinicians from institutions across the United States who specialize in pancreatic cancer. The board provides scientific and clinical expertise to guide the organization in planning and implementing its research initiatives and its information and education services for patients, families, caregivers and healthcare professionals. The organization has a large grass-roots component and involves millions of individuals across the United States who have an interest in or have been affected by the disease.
Simeone is the founding director of the University of Michigan Pancreatic Cancer Center. She also serves as the director for the U-M Multidisciplinary Pancreatic Cancer Clinic and leads the Translational Oncology Program at the university’s North Campus Research Complex. She is an active clinician and participates in every aspect of clinical care, including clinical trials. She is distinguished as an internationally recognized expert in pancreatic cancer and leads a large research program focused on early detection, understanding the molecular underpinnings of metastasis and development of more effective therapeutic strategies to treat the disease. She is past president of the American Pancreatic Association and Society of University Surgeons, and currently serves on the National Cancer Institute Pancreatic Cancer Task Force. Simeone is a member of the Institute of Medicine of the National Academies.